JNPMEDI signed an MOU with Medirama to develop a clinical trial solution for anti-cancer drugs.
JNPMEDI
JNPMEDI announced on March 22nd that it had signed an MOU with Medirama for the development of clinical trial services for anticancer drugs. The two companies plan to develop clinical medical data solutions specialized in anticancer drugs with the goal of strengthening the competitiveness of digital-based clinical services. To this end, they have decided to establish a business cooperation system.
JNPMEDI announced on March 22nd that it had signed an MOU with Medirama for the development of clinical trial services for anticancer drugs. The two companies plan to develop clinical medical data solutions specialized in anticancer drugs with the goal of strengthening the competitiveness of digital-based clinical services. To this end, they have decided to establish a business cooperation system.
JNPMEDI plans to strengthen the service competitiveness of Maven Clinical Cloud in cooperation with Medirama.
"Clinical trials for anticancer drugs require a lot of investment in terms of time and money," said Kwunho Jeong, CEO of JNPMEDI. "We will do our best to develop functions that can increase work efficiency."
Hanlim Moon, MD, PhD and CEO of Medirama, said, "Medirama provides consulting services for optimized clinical plans to collaborators and operates planned clinical trials in the shortest time to maximize win-win (synergy) effects. We will create a case that presents new possibilities in the success of new drug development through collaboration with JNPMEDI."